- Home
- LRE vs PULM Comparison
LRE vs PULM Comparison
Compare LRE & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- PULM
- Stock Information
- Founded
- LRE 2001
- PULM 2003
- Country
- LRE Japan
- PULM United States
- Employees
- LRE N/A
- PULM N/A
- Industry
- LRE
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- PULM Health Care
- Exchange
- LRE Nasdaq
- PULM Nasdaq
- Market Cap
- LRE 24.0M
- PULM 20.5M
- IPO Year
- LRE 2023
- PULM N/A
- Fundamental
- Price
- LRE $1.65
- PULM $5.33
- Analyst Decision
- LRE
- PULM
- Analyst Count
- LRE 0
- PULM 0
- Target Price
- LRE N/A
- PULM N/A
- AVG Volume (30 Days)
- LRE 8.5K
- PULM 9.1K
- Earning Date
- LRE 01-01-0001
- PULM 08-12-2025
- Dividend Yield
- LRE N/A
- PULM N/A
- EPS Growth
- LRE N/A
- PULM N/A
- EPS
- LRE N/A
- PULM N/A
- Revenue
- LRE $110,330,328.00
- PULM $1,921,000.00
- Revenue This Year
- LRE N/A
- PULM N/A
- Revenue Next Year
- LRE N/A
- PULM $134.88
- P/E Ratio
- LRE N/A
- PULM N/A
- Revenue Growth
- LRE 3.92
- PULM N/A
- 52 Week Low
- LRE $1.10
- PULM $1.78
- 52 Week High
- LRE $2.49
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- LRE 41.55
- PULM 33.68
- Support Level
- LRE $1.61
- PULM $5.20
- Resistance Level
- LRE $1.85
- PULM $5.77
- Average True Range (ATR)
- LRE 0.09
- PULM 0.29
- MACD
- LRE -0.03
- PULM -0.03
- Stochastic Oscillator
- LRE 7.41
- PULM 9.93
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).